7DICHIARA J, BLIDEN K P, TANTRY U S, et al. Platelet function measured by VerifyNowtrade mark identifies generalized high platelet reactivity in aspirin treated patients[J]. Platelets,2007,18 (6) :414 - 423.
8GURBEL P A,BLIDEN K P,DICHIARA Jr et al. Evaluation of dose - related effects of aspirin on platelet function: results from the aspirin-induced platelet effect (ASPECT) study[J]. Circulation, 2007 26,115(25) : 3156 - 3164.
9TANAKA K A, SZLAM F, SUN H Y, et al. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin[J]. Anesth Analg, 2007,105(4) ; 933 - 939.
10YOUNG G, YONEKAWA K E, NAKAGAWA P A, et al. Recombinant activated factor Ⅶ effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivallrudin ex vivo as measured using thromboelastography[J]. Blood Coagul Fibrinolysis, 2007, 18 (6) :547 - 553.
4Royston D,yon Kier S.Reduced haemostatic factor transfusion using heparinase-mondiied thrombelastography during cardiopulmonary bypass.Br J Anaesth,2001,86:575-578.
5Narani KK.Thrombelastography in the perioperative period.Indian J Anaesth,2005,49:89-95.
6Cammerer U,Dietrich W,Rampf T,et al.The predictive value of modified computerized thromboelastography and platelet function anaIysis for postoperative blood loss in routine cardiac surgery.Anesth Aanlg,2003,96:51-57.
7Chandler W L.The thrombelastography and the thrombitastography technique.Semin Thromb Hemost,1995,21(S4):1-6.
8Chavez JJ,Foley DE,Snider CC,et al.A novel thrombelastograph tissue factor/kaolin assay of activated clotting times for monitoring heparin anticoagulation during cardiopulmonary bypass.Anesth Aanlg,2004,99:1290-1294.
9Stover EP et al. Anesthesiology . 1998
10Mallett SV et al. British Journal of Anaesthesia . 1992
9Michelle M. Graham Outcomes of aider-hours versus regular working hours primary percutaneous coronary intervention for acute myocar- dial infarction [J]. BMJ Qual Saf Health Care, 2011,20(1): 60-67.
10Aronow HD. Bleeding risk associated with lyear of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial [J]. Am Heart J, 2009,157(2):369-374.
